FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ORBIMED ADVISORS LLC 		2. Issuer Name and Ticker or Trading Symbol

COMPLETE GENOMICS INC [ GNOM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

767 THIRD AVENUE, 30TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/16/2010
(Street)

NEW YORK, NY 10017
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001   11/16/2010     C    2252898   A   (1) 2252898   I   See Footnotes   (2) (3) (5)
Common Stock, par value $0.001   11/16/2010     C    1267070   A   (1) 3519968   I   See Footnotes   (2) (3) (5)
Common Stock, par value $0.001   11/16/2010     P (8)    597091   A $9.00   4117059   I   See Footnotes   (2) (3) (5)
Common Stock, par value $0.001   11/16/2010     C    21456   A   (1) 21456   I   See Footnotes   (2) (4) (5)
Common Stock, par value $0.001   11/16/2010     C    12068   A   (1) 33524   I   See Footnotes   (2) (4) (5)
Common Stock, par value $0.001   11/16/2010     P (8)    5687   A $9.00   39211   I   See Footnotes   (2) (4) (5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series D Preferred Stock     (1) 11/16/2010     C         2252898      (6)   (7) Common Stock   2252898     (1) 0   I   See Footnotes   (2) (3) (5)
Series D Preferred Stock     (1) 11/16/2010     C         21456      (6)   (7) Common Stock   21456     (1) 0   I   See Footnotes   (2) (4) (5)
Series E Preferred Stock     (1) 11/16/2010     C         1267070      (6)   (7) Common Stock   1267070     (1) 0   I   See Footnotes   (2) (3) (5)
Series E Preferred Stock     (1) 11/16/2010     C         12068      (6)   (7) Common Stock   12068     (1) 0   I   See Footnotes   (2) (4) (5)

Explanation of Responses:
( 1)  Each share of Series D and Series E Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering.
( 2)  The shares of Preferred Stock and shares of Common Stock (together "Shares")reported herein as indirectly beneficially owned by OrbiMed Capital GP III LLC ("Capital"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly") are directly owned by OrbiMed Private Investments III, LP (formerly, Caduceus Private Investments III, LP) ("OPI III") and OrbiMed Associates III, LP ("Associates"). Each of Capital, Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by OPI III and each of Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by Associates. This Form 4 is being jointly filed by Capital, Advisors and Isaly. The Reporting Persons have designated a representative, currently Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors.
( 3)  These Shares are beneficially owned by OPI III. Capital is the sole general partner of OPI III. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital. Advisors and Capital may be deemed to have beneficial ownership of Shares held by OPI III by virtue of such relationships. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
( 4)  These Shares are beneficially owned by Associates. Advisors is the sole general partner of Associates and may be deemed to have beneficial ownership of Shares held by Associates by virtue of that relationship. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
( 5)  Each of Advisors, Capital and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
( 6)  The securities are immediately convertible.
( 7)  The expiration date is not relevant to the conversion of these securities.
( 8)  OPI III purchased an additional 597,091 shares of Common Stock and Associates purchased an additional 5,687 shares of Common Stock in connection with the initial public offering at the offering price of $9.00 per share.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ORBIMED ADVISORS LLC
767 THIRD AVENUE, 30TH FLOOR
NEW YORK, NY 10017
X


Signatures
/s/ Samuel D. Isaly 11/16/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Global X Genomics and Bi... Charts.
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Global X Genomics and Bi... Charts.